23/09/2026 Roche’s sefaxersen significantly reduced proteinuria in IgA nephropathy Roche’s sefaxersen significantly reduced proteinuria in IgA nephropathy (Ref) Roche reported positive prespecified interim results from Ph3 IMAgINATION study of sefaxersen (ASO targeting complement factor B) in adults with primary IgA nephropathy (IgAN). The trial met its primary endpoint, demonstrating statistically significant and clinically meaningful improvements in proteinuria reduction vs